cd-18

Dexamethasone is a glucocorticoid receptor agonist and IL receptor modulator with anti-inflammatory, immunosuppressive, and apoptosis-inducing activities. It inhibits the production of inflammatory miRNA-155 exosomes in macrophages, significantly reduces inflammatory cytokine expression in neutrophils and monocytes, suppresses LPS-induced macrophage inflammation, and induces autophagy. It is commonly used to induce animal models of depression, muscle atrophy, and hypertension, and holds potential in COVID-19 research.

J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect. J-113863 is a potent and selective CCR1 (CD18) antagonist with IC50 values of 0.9 nM and 5.8 nM for human and mouse CCR1 receptors, respectively.

Leukadherin-1 is an allosteric activator of CD11b/CD18. Increasing CD11b/CD18-dependent cell adhesion to fibrinogen, Decreasing leukocyte motility and transendothelial migration; reduces inflammation.

Anti-Mouse CD18 Antibody (M18/2) is a rat-derived IgG2a, κ antibody inhibitor that targets mouse CD18.

Anti-CXCR4/CD184 Antibody is a CHO-expressed humanized antibody targeting CXCR4/CD184. It features a huIgG1 heavy chain and huλ light chain, with an estimated molecular weight (MW) of 145 kDa. For isotype controls, refer to HumanIgG1kappa, Isotype Control.

The compound, Anti-CXCR3/GPR9/CD183 Antibody, is a humanized antibody expressed in CHO, targeting CXCR3/GPR9/CD183. It features huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. For isotype control, please refer to HumanIgG1kappa, Isotype Control.

The Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an IgG antibody inhibitor derived from a hamster originating from the United States, specifically targeting mouse CXCR3/CD183.

Anti-CD185/CXCR5 Antibody is an antibody inhibitor targeting human CD185/CXCR5.

JAK1-IN-18 (Example 2) is a selective JAK1 inhibitor with an IC50 value of 0.15 nM, demonstrating significantly greater inhibitory potency for JAK1 compared to JAK2 and JAK3. It significantly reduces inflammation in ulcerative colitis (UC) mouse models induced by DSS and Crohn's disease (CD) rat models induced by DNBS. JAK1-IN-18 is applicable for research into autoimmune diseases (such as inflammatory bowel disease), viral infections (such as hepatitis B virus infection), and cancers (such as hematologic malignancies).